[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Larimar Therapeutics Inc (LRMR)

Larimar Therapeutics Inc (LRMR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Larimar Therapeutics Inc THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 USA

https://larimartx.com Employees: 71 P: 844-511-9056

Sector:

Medical

Description:

Larimar Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing treatments for rare diseases. The company's lead product consist CTI-1601, which is in clinical stage. Larimar Therapeutics Inc., formerly known as Zafgen Inc., is based in BALA CYNWYD, Pa.

Key Statistics

Overview:

Market Capitalization, $K 371,901
Enterprise Value, $K 286,491
Shares Outstanding, K 103,883
Float, K 99,208
% Float 95.50%
Short Interest, K 7,333
Short Float 7.06%
Days to Cover 4.97
Short Volume Ratio 0.17
% of Insider Shareholders 4.50%
% of Institutional Shareholders 91.92%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ -165,670 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -62,500 K
EBIT, $ -172,500 K
EBITDA, $ -173,850 K

Growth:

1-Year Return 91.44%
3-Year Return -2.19%
5-Year Return -76.02%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 36.41%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.73 on 03/19/26
Next Earnings Date 08/13/26
Earnings Per Share ttm -2.21
EPS Growth vs. Prev Qtr 57.53%
EPS Growth vs. Prev Year 32.61%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-12 on 05/29/20

LRMR Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -147.79%
Return-on-Assets % -103.07%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 4.12
Book Value/Share 0.94
Interest Coverage -8.07
60-Month Beta 0.91
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.